Related Experiment Video
Updated: Feb 25, 2026
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
MiR-520b inhibits the development of glioma by directly targeting MBD2
Sitong Cui1, Liang Liu1, Teng Wan1
1Department of Neurosurgery, Nanjing First Hospital, Nanjing Medical UniversityNanjing 210006, Jiangsu, China.
Abstract:
MicroRNAs play important roles in the process of cancer, which microRNA-520b (miR-520b) has been reported to play critical roles in tumor progression in many types of cancers. However, its role in glioma remains unknown. In this study, we found that miR-520b could inhibit growth and progression in glioma by targeting methyl-CpG-binding domain 2 (MBD2). First, we analyzed the expression of miR-520b in different glioma grades and different cell lines (U87, U251 and astrocyte). Then we assessed the effect of miR-520b on glucose metabolism, invasion, angiogenesis and chemosensitivity in U87 and U251 cells. By using an online database, miR-520b was found to directly bind to the 3'-untranslated regions (3'-UTR) of MBD2 and reduce its expression at the protein level, which further inhibits the development of glioma. MBD2 was also found to be over-expressed in human glioma tissues and in U87 and U251 cells and its level was inversely correlated with that of miR-520b. Furthermore, restoration of MBD2 partially rescued the miR-520b-induced inhibitory effect on glucose metabolism, invasion, angiogenesis and chemosensitivity in glioma cells. In summary, to date, this is the first study to demonstrate that miR-520b functions as a tumor suppressor in glioma by directly targeting MBD2, suggesting that MBD2 may be a potential therapeutic target for glioma.
Insights
MicroRNA-520b (miR-520b) suppresses glioma growth by targeting methyl-CpG-binding domain 2 (MBD2). This finding reveals miR-520b as a potential therapeutic target for glioma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) are crucial in cancer development.
- microRNA-520b (miR-520b) has known roles in various cancers, but its function in glioma was unclear.
- Glioma is a primary brain tumor with significant unmet therapeutic needs.
Purpose of the Study:
- To investigate the role of miR-520b in glioma progression.
- To identify the molecular targets of miR-520b in glioma.
- To explore the therapeutic potential of miR-520b in glioma.
Main Methods:
- Analysis of miR-520b expression in glioma tissues and cell lines.
- Assessment of miR-520b's impact on glioma cell metabolism, invasion, angiogenesis, and chemosensitivity.
- Bioinformatic prediction and experimental validation of miR-520b targets, specifically methyl-CpG-binding domain 2 (MBD2).
- Restoration experiments to confirm MBD2's role in mediating miR-520b effects.
Main Results:
- miR-520b expression was analyzed in different glioma grades and cell lines.
- miR-520b inhibited glucose metabolism, invasion, angiogenesis, and enhanced chemosensitivity in glioma cells.
- miR-520b directly targets the 3'-untranslated region (3'-UTR) of MBD2, reducing its protein expression.
- MBD2 was overexpressed in glioma tissues and inversely correlated with miR-520b levels.
- Restoring MBD2 expression partially reversed the inhibitory effects of miR-520b.
Conclusions:
- This study demonstrates that miR-520b acts as a tumor suppressor in glioma.
- miR-520b exerts its tumor-suppressive function by directly targeting MBD2.
- MBD2 represents a potential therapeutic target for glioma treatment.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:22MicroRNAs